Bajaj Healthcare's Q3 & 9M FY26 Results: 31% Revenue Growth Amid Global Volatility

Bajaj Healthcare Limited, a leading manufacturer of APIs, Intermediates and Formulations, announced its financial results for the quarter and nine months ended 31° Dec 2025. The company reported a 31% year-on-year increase in revenue, driven by a 35% increase in EBITDA and a robust growth in API exports. The domestic API business also grew by 15%, despite pricing pressure. The formulations business is contributing significantly to the company's growth. The CDMO business is also gaining traction. The company is advancing its CNS portfolio, with recently secured CDSCO approval for Suvorexant trials and the launch of Magtein. The company is focusing on high-potential therapeutic areas and expanding its presence in regulated markets.